Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 63

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 63
---
 that we may develop, and our technology may be adversely affected; |

| ● | We will continue to incur increased costs as a result of operating as a public company, and our management will continue to devote substantial time to new compliance initiatives; and |

| ● | The other matters described in the section titled “Risk Factors” beginning on page 4. |

We caution you against
placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as
of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date of this prospectus.
We undertake no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs.
In the event that any forward-looking statement is updated, no inference should be made that we will make additional updates with respect
to that statement, related matters, or any other forward-looking statements. Any corrections or revisions and other important assumptions
and factors that could cause actual results to differ materially from forward-looking statements, including discussions of significant
risk factors, may appear in our public filings with the SEC, which are or will be (as appropriate) accessible at www.sec.gov, and which
you are advised to consult. For additional information, please see the section titled “Where You Can Find More Information; Incorporation
of Information by Reference” elsewhere in this prospectus.

Market, ranking and industry
data used throughout this prospectus, including statements regarding market size and technology adoption rates, is based on the good faith
estimates of our management, which in turn are based upon our management’s review of internal surveys, independent industry surveys
and publications including third party research and publicly available information. These data involve a number of assumptions and limitations,
and you are cautioned not to give undue weight to such estimates. While we are not aware of any misstatements regarding the industry data
presented herein, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed
under the heading “Risk Factors” in this prospectus and in and “Risk Factors” and “Operating and Financial Review and Prospects” in our 2022 Annual Report on Form 20-F filed with the SEC on March 9, 2023 and
incorporated by reference into this prospectus, or our Annual Report.

<div align='center'>6

CAPITALIZATION</div>

We intend to include information about our capitalization
and indebtedness in the prospectus and applicable prospect